Approval of bortezomib has validated ubiquitin-proteasome pathway as an important target
for treatment of haematological malignancies. However, clinical shortcomings of bortezomib,
a covalent peptide proteasome inhibitor, has prompted a paradigm shift in anti-proteasome
drug discovery towards development of non-peptidic inhibitors and targeting of upstream
ubiquitin system which has drawn traction for interdisciplinary forays. It is being widely
recognized that natural products provide valuable leads in the discovery of potent …